Overview
Current Appointments & Affiliations
Professor of Pediatrics
·
2021 - Present
Pediatrics, Nephrology,
Pediatrics
Chief, Division of Pediatric Nephrology
·
2016 - Present
Pediatrics, Nephrology,
Pediatrics
Recent Publications
Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
Journal Article Kidney International Reports · June 1, 2021 Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare, complex, multisystem disease of dysregulated complement activity, characterized by progressive thrombotic microangiopathy (TMA), acute kidney injury, and multiorgan dysfunction, which often ... Full text CiteCorrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.
Journal Article Kidney Int · May 2021 Full text Link to item CiteErratum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D, Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment" Kidney Int. 2020;97:1287-1296.
Journal Article Kidney Int · December 2020 Full text Link to item CiteRecent Grants
Single arm Study of ALXN1210 in Complement Inhibitor Treatment-Naive Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2022A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)
Clinical TrialPrincipal Investigator · Awarded by Alexion Pharmaceuticals, Inc. · 2017 - 2020Vifor PA21 Phaslyra
Clinical TrialPrincipal Investigator · Awarded by Vifor Fresenius Medical Care Renal Pharma · 2016 - 2019View All Grants
Education, Training & Certifications
Kasturba Medical College (Manipal) ·
1982
M.B.B.S.